Across TCGA pan-cancer cohorts, CENPA mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CENPA data layer compared with 30 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher CENPA mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CENPA expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.
GBM and HNSC are the cancer types where CENPA mass-spec protein most reproducibly stratifies survival.